A Randomized Controlled Trial to Assess the Efficacy of Tiotropium in Canadian Patients with Chronic Obstructive Pulmonary Disease

Simple item page
dc.contributor.authorChan, Charles KN
dc.contributor.authorMaltais, François
dc.contributor.authorSigouin, Chris
dc.contributor.authorHaddon, Jennifer M
dc.contributor.authorFord, Gordon T
dc.contributor.authoron behalf of the SAFE Study Group,
dc.date.accessioned2018-09-27T12:13:55Z
dc.date.available2018-09-27T12:13:55Z
dc.date.issued2007-01-01
dc.date.updated2018-09-27T12:13:54Z
dc.description.abstractBACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV1) than those patients who have stopped smoking.OBJECTIVES: To assess the effect of tiotropium on pre-dose (trough) FEV1 in patients with COPD followed in Canada.METHODS: A total of 913 patients were randomly assigned to receive either tiotropium 18 μg once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study. The effect of tiotropium on measurements of lung function (FEV1, FEV6 and forced vital capacity), symptoms, health-related quality of life (St George’s Respiratory Questionnaire) and exacerbations were examined.RESULTS: Tiotropium improved trough FEV1 in both current and ex-smokers compared with placebo. Baseline FEV1 in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (Pud_less_than0.001). At week 48, the mean difference between the tiotropium and placebo groups was 0.14±0.04 L (Pud_less_than0.001) in the smoker group and 0.08±0.02 L (Pud_less_than0.0001) in the ex-smoker group. Tiotropium also significantly improved trough forced vital capacity and FEV6 compared with placebo throughout the treatment period (Pud_less_than0.05, for all). Furthermore, tiotropium significantly improved the St George’s Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, Pud_less_than0.005).CONCLUSIONS: Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.
dc.description.versionPeer Reviewed
dc.identifier.citationCharles KN Chan, François Maltais, Chris Sigouin, Jennifer M Haddon, Gordon T Ford, and on behalf of the SAFE Study Group, “A Randomized Controlled Trial to Assess the Efficacy of Tiotropium in Canadian Patients with Chronic Obstructive Pulmonary Disease,” Canadian Respiratory Journal, vol. 14, no. 8, pp. 465-472, 2007. doi:10.1155/2007/192961
dc.identifier.doihttps://doi.org/10.1155/2007/192961
dc.identifier.urihttp://hdl.handle.net/1880/108526
dc.language.rfc3066en
dc.rights.holderCopyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.titleA Randomized Controlled Trial to Assess the Efficacy of Tiotropium in Canadian Patients with Chronic Obstructive Pulmonary Disease
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CRJ.2007.192961.pdf
Size:
200.13 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications